<![CDATA[ImmunoMet Therapeutics, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37029>Mon, 27 Apr 2026 12:20:39 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting]]>https://www.newswire.co.kr/newsRead.php?no=1005033Thu, 30 Jan 2025 11:55:00 +0900<![CDATA[이뮤노멧 테라퓨틱스, ASCO-GI 회의에서 췌장암의 릭수미스타트 임상 1b상 연구 데이터 업데이트 발표]]>https://www.newswire.co.kr/newsRead.php?no=1005034Thu, 30 Jan 2025 11:55:00 +0900<![CDATA[ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer]]>https://www.newswire.co.kr/newsRead.php?no=956018Fri, 18 Nov 2022 16:20:00 +0900<![CDATA[이뮤노멧 테라퓨틱스, IM156의 췌장암 관련 1b상 시험에서 최초로 환자 대상 투여]]>https://www.newswire.co.kr/newsRead.php?no=956019Fri, 18 Nov 2022 16:20:00 +0900<![CDATA[Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer]]>https://www.newswire.co.kr/newsRead.php?no=927773Tue, 27 Jul 2021 14:00:00 +0900<![CDATA[이뮤노멧 테라퓨틱스, 최고의료책임자에 레바티 시러니와스 박사 선임]]>https://www.newswire.co.kr/newsRead.php?no=927774Tue, 27 Jul 2021 14:00:00 +0900<![CDATA[ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis]]>https://www.newswire.co.kr/newsRead.php?no=922762Tue, 04 May 2021 14:10:00 +0900<![CDATA[이뮤노멧 테라퓨틱스의 IM156, 미 FDA 신속심사대상 지정]]>https://www.newswire.co.kr/newsRead.php?no=922764Tue, 04 May 2021 14:10:00 +0900<![CDATA[ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing]]>https://www.newswire.co.kr/newsRead.php?no=918403Tue, 09 Feb 2021 14:30:00 +0900<![CDATA[이뮤노멧 테라퓨틱스, FDA서 특발성 폐섬유증 치료 후보물질 IM156에 대한 임상시험계획 승인과 희귀의약품 지정받고 자금 조달 마감]]>https://www.newswire.co.kr/newsRead.php?no=918404Tue, 09 Feb 2021 14:30:00 +0900